Antibody-Mediated Enhancement of Human Immunodeficiency Virus Type 1 Infectivity Is Determined by the Structure of gp120 and Depends on Modulation of the gp120-CCR5 Interaction

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Journal of Virology

• Publication date

  2002-03-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/JVI.76.6.2827-2834.2002PMID 11861850PMCID PMC135957
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Epitope Mapping of CCR5 Reveals Multiple Conformational States and Distinct but Overlapping Structures Involved in Chemokine and Coreceptor Function*

  1999cited by this paper
• Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo.

  1999cited by this paper
• The CC-Chemokine RANTES Increases the Attachment of Human Immunodeficiency Virus Type 1 to Target Cells via Glycosaminoglycans and Also Activates a Signal Transduction Pathway That Enhances Viral Infectivity

  1999cited by this paper
• Human immunodeficiency virus-1 infection requires pertussis toxin sensitive G-protein-coupled signalling and mediates cAMP downregulation.

  1999cited by this paper
• Evidence that Antibody-Mediated Neutralization of Human Immunodeficiency Virus Type 1 by Sera from Infected Individuals Is Independent of Coreceptor Usage

  1998cited by this paper
• Mutations in both gp120 and gp41 Are Responsible for the Broad Neutralization Resistance of Variant Human Immunodeficiency Virus Type 1 MN to Antibodies Directed at V3 and Non-V3 Epitopes

  1998cited by this paper
• The antigenic structure of the HIV gp120 envelope glycoprotein

  1998cited by this paper
• Neutralization Sensitivity of Human Immunodeficiency Virus Type 1 Primary Isolates to Antibodies and CD4-Based Reagents Is Independent of Coreceptor Usage

  1998cited by this paper
• Determinants of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Activation by Soluble CD4 and Monoclonal Antibodies

  1998cited by this paper
• A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding.

  1998cited by this paper
• Identification of Determinants on a Dualtropic Human Immunodeficiency Virus Type 1 Envelope Glycoprotein That Confer Usage of CXCR4

  1998cited by this paper
• Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

  1998cited by this paper
• Coreceptor Utilization by Human Immunodeficiency Virus Type 1 Is Not a Primary Determinant of Neutralization Sensitivity

  1998cited by this paper
• HIV entry and its inhibition.

  1998cited by this paper
• Human retroviruses and AIDS 1996. A compilation and analysis of nucleic acid and amino acid sequences

  1997cited by this paper
• Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor

  1997cited by this paper
• The role of viral phenotype and CCR-5 gene defects in HIV-1 transmission and disease progression

  1997cited by this paper
• Interaction of Chemokine Receptor CCR5 with its Ligands: Multiple Domains for HIV-1 gp120 Binding and a Single Domain for Chemokine Binding

  1997cited by this paper
• Inhibition of Virus Attachment to CD4+ Target Cells Is a Major Mechanism of T Cell Line–adapted HIV-1 Neutralization

  1997cited by this paper
• CD4, CXCR-4, and CCR-5 dependencies for infections by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1

  1997cited by this paper
• Mechanism of Transdominant Inhibition of CCR5-mediated HIV-1 Infection by ccr5Δ32*

  1997cited by this paper
• Change in Coreceptor Use Correlates with Disease Progression in HIV-1–Infected Individuals

  1997cited by this paper
• Modulation of primary human immunodeficiency virus type 1 envelope glycoprotein-mediated entry by human antibodies.

  1997cited by this paper
• Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype

  1997influential reference
• CD4-independent infection by human immunodeficiency virus type 2 strain ROD/B: the role of the N-terminal domain of CXCR-4 in fusion and entry

  1997influential reference
• CD4-independent infection by HIV-2 (ROD/B): use of the 7-transmembrane receptors CXCR-4, CCR-3, and V28 for entry.

  1997cited by this paper
• Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement

  1996cited by this paper
• CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5

  1996cited by this paper
• CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5

  1996cited by this paper
• Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene

  1996cited by this paper
• Antibody neutralization of HIV-1.

  1996cited by this paper
• Analysis of Neutralizing and Enhancing Antibodies to Human Immunodeficiency Virus Type 1 Primary Isolates in Plasma of Individuals Infected with env Genetic Subtype B and E Viruses in Thailand

  1996cited by this paper
• CD4-independent infection by HIV-2 is mediated by fusin/CXCR4.

  1996cited by this paper
• Primary, syncytium-inducing human immunodeficiency virus type 1 isolates are dual-tropic and most can use either Lestr or CCR5 as coreceptors for virus entry

  1996cited by this paper
• Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates

  1995cited by this paper
• Equal levels of gp120 retention and neutralization resistance of phenotypically distinct primary human immunodeficiency virus type 1 variants upon soluble CD4 treatment

  1995cited by this paper
• Update on the neutralisation of animal viruses

  1995cited by this paper
• Neutralization of primary HIV‐1 isolates by anti‐envelope monoclonal antibodies

  1995cited by this paper
• Enhancement of Infectivity of a Non‐Syncytium Inducing HIV‐1 by sCD4 and by Human Antibodies that Neutralize Syncytium Inducing HIV‐1

  1995cited by this paper
• Blood Monocytes Infected In Vivo by HIV-1 Variants with a Syncytium-Inducing Phenotype

  1994cited by this paper
• Both the V2 and V3 regions of the human immunodeficiency virus type 1 surface glycoprotein functionally interact with other envelope regions in syncytium formation

  1993cited by this paper
• Further characterization of an antigenic site of HIV-1 gp120 recognized by virus neutralizing human monoclonal antibodies.

  1993cited by this paper
• Ig CDR3-like region of the CD4 molecule is involved in HIV-induced syncytia formation but not in viral entry.

  1993cited by this paper
• Human immunodeficiency virus type 2 infection and fusion of CD4-negative human cell lines: induction and enhancement by soluble CD4

  1992influential reference
• Truncation of the human immunodeficiency virus type 1 transmembrane glycoprotein cytoplasmic domain blocks virus infectivity

  1992cited by this paper
• Genetic and Functional Analysis of a Set of HIV-1 Envelope Genes Obtained from Biological Clones with Varying Syncytium-Inducing Capacities

  1992cited by this paper
• Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding

  1991cited by this paper
• Human immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein

  1991cited by this paper
• Differential loss of envelope glycoprotein gp120 from virions of human immunodeficiency virus type 1 isolates: effects on infectivity and neutralization

  1991cited by this paper
• Differences in affinity of anti-CD4 monoclonal antibodies predict their effects on syncytium induction by human immunodeficiency virus.

  1990cited by this paper
• Characterization of the fusion domain of the human immunodeficiency virus type 1 envelope glycoprotein gp41.

  1990cited by this paper
• Rapid complementation assays measuring replicative potential of human immunodeficiency virus type 1 envelope glycoprotein mutants

  1990cited by this paper
• Oligomeric structure of the human immunodeficiency virus type 1 envelope glycoprotein.

  1990cited by this paper
• Novel anti-CD4 monoclonal antibodies separate human immunodeficiency virus infection and fusion of CD4+ cells from virus binding

  1990cited by this paper
• Emergence of viruses resistant to neutralization by V3-specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees

  1990cited by this paper
• Structural analysis of the human immunodeficiency virus-binding domain of CD4. Epitope mapping with site-directed mutants and anti-idiotypes

  1989cited by this paper
• Oligomeric structure of gp41, the transmembrane protein of human immunodeficiency virus type 1

  1989cited by this paper
• A simple phase-extraction assay for chloramphenicol acyltransferase activity.

  1988cited by this paper

• Molecular Mechanisms of Antibody-Dependent Enhancement of Viral Infection

  2026cites this paper
• Enhancement of viral infection by antibodies and consequences

  2025cites this paper
• Enterovirus A71 priorities, challenges, and future opportunities in humoral immunity and vaccine development

  2025cites this paper
• Enhanced Assessment of Cross-Reactive Antigenic Determinants within the Spike Protein

  2024cites this paper
• Association of CR2 genotypes with the acquisition of HIV infection in a trial of recombinant glycoprotein 120 Vaccine.

  2020cites this paper
• Antibody-dependent enhancement of coronaviruses

  2020cites this paper
• Association of complemen t C3d receptor 2 genotypes with the acquisition of HIV infection in a trial of recombinant glycoprotein 120 vaccine

  2019cites this paper
• Antibody-Dependent Enhancement of Viral Infections

  2019cites this paper
• Viral-Induced Enhanced Disease Illness

  2018cites this paper
• Increasing the Clinical Potential and Applications of Anti-HIV Antibodies

  2017cites this paper
• The Comparative Value of Feline Virology Research: Can Findings from the Feline Lentiviral Vaccine Be Translated to Humans?

  2017cites this paper
• Relationship between Vaccine-Induced Antibody Capture of Infectious Virus and Infection Outcomes following Repeated Low-Dose Rectal Challenges with Simian Immunodeficiency Virus SIVmac251

  2016cites this paper
• Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates

  2016cites this paper
• Could vaccination with AIDSVAX immunogens have resulted in antibody-dependent enhancement of HIV infection in human subjects?

  2014cites this paper
• The Neonatal Fc Receptor (FcRn) Enhances Human Immunodeficiency Virus Type 1 (HIV-1) Transcytosis across Epithelial Cells

  2013cites this paper
• Antibody-dependent enhancement and the risk of HIV infection.

  2013cites this paper
• Monoclonal antibodies directed against protective antigen of Bacillus anthracis enhance lethal toxin activity in vivo.

  2011cites this paper
• UV and X‐ray structural studies of a 101‐residue long Tat protein from a HIV‐1 primary isolate and of its mutated, detoxified, vaccine candidate

  2010cites this paper
• Deglycosylation or Partial Removal of HIV-1 CN54 gp140 V1/V2 Domain Enhances Env-Specific T Cells

  2009cites this paper
• FIV vaccine development: a continuing challenge

  2008cites this paper
• Fc receptor-mediated, antibody-dependent enhancement of bacteriophage lambda-mediated gene transfer in mammalian cells.

  2008cites this paper
• Enhancement of HIV infection by cellulose sulfate.

  2008cites this paper
• Vaccine-induced enhancement of viral infections

  2008cites this paper
• HIV-1 neutralization: mechanisms and relevance to vaccine design.

  2007cites this paper
• Design and characterization of an HIV-1 Tat mutant: inactivation of viral and cellular functions but not antigenicity.

  2007cites this paper
• The role of macrophages and anti-viral antibodies in West Nile virus pathogenesis

  2006cites this paper
• Evidence for CTL-Mediated Selection of Tat and Rev Mutants after the Onset of the Asymptomatic Period during HIV Type 1 Infection

  2006cites this paper
• Engineering therapeutic antibody fragments targeting the anthrax toxin

  2005cites this paper
• Selective Modification of Variable Loops Alters Tropism and Enhances Immunogenicity of Human Immunodeficiency Virus Type 1 Envelope

  2004cites this paper
• Antibody‐dependent enhancement of viral infection: molecular mechanisms and in vivo implications

  2003cites this paper
• Adaptive Changes after Human Immunodeficiency Virus Type 1 Transmission

  2002cites this paper
• Activation of gp120 of human immunodeficiency virus by their V3 loop-derived peptides.

  2002cites this paper